1. Combination of ω-3 fatty acids and cisplatin as a potential alternative strategy for personalized therapy of metastatic melanoma: an in-vitro study
   Renata Ottes Vasconcelos et al, 2019, Melanoma Research CrossRef
2. Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-S
   Maria Di Bartolomeo et al, 2021, Tumori Journal CrossRef
3. Overexpression of TACC3 in Breast Cancer Associates With Poor Prognosis
   Haiping Song et al, 2018, Applied Immunohistochemistry & Molecular Morphology CrossRef
4. Extensive analysis of the molecular biomarkers excision repair cross complementing 1, ribonucleotide reductase M1, β-tubulin III, thymidylate synthetase, and topoisomerase IIα in breast cancer
   Juncheng Li et al, 2021, Medicine CrossRef
5. BRCA1 expression associated with the prognostic value of platinum-based chemotherapy for stage II–IV non-small cell lung cancer: A meta-analysis
   Zhenhua Huang et al, 2022, The International Journal of Biological Markers CrossRef
6. Association between the XRCC1 polymorphisms and clinical outcomes of advanced NSCLC treated with platinum-based chemotherapy: a meta-analysis based on the PRISMA statement
   Dan-Juan Li et al, 2017, BMC Cancer CrossRef
7. FDG PET/CT Tumor Dissemination Characteristic Predicts the Outcome of First-Line Systemic Therapy in Non-small Cell Lung Cancer
   Weiyue Tan et al, 2023, Academic Radiology CrossRef
8. Double-staining Immunohistochemistry Reveals in Malignant Pleural Mesothelioma the Coexpression of ERCC1 and RRM1 as a Frequent Biological Event Related to Poorer Survival
   Federica Zito Marino et al, 2021, Applied Immunohistochemistry & Molecular Morphology CrossRef
9. Expression levels of MRP1, GST-π, and GSK3β in ovarian cancer and the relationship with drug resistance and prognosis of patients
   Xiaojing Tong et al, 2019, Oncology Letters CrossRef
10. Pretreatment albumin/fibrinogen ratio as a promising predictor for the survival of advanced non small-cell lung cancer patients undergoing first-line platinum-based chemotherapy
    Jun Ying et al, 2019, BMC Cancer CrossRef
11. ERCC1 and ERCC2 Polymorphisms Predict the Efficacy and Toxicity of Platinum-Based Chemotherapy in Small Cell Lung Cancer
    Andrés Barba et al, 2024, Pharmaceutics CrossRef
12. Characterization of Non-Small Cell Lung Cancer Tissue by Quantitative Assessment of Class III β-Tubulin Expression
    A. Lee et al, 2024, Antibiot Khimioter = Antibiotics and Chemotherapy CrossRef
13. Role of adjuvant therapy in T1-2N0 resected non–small cell lung cancer
    Gavitt A. Woodard et al, 2022, The Journal of Thoracic and Cardiovascular Surgery CrossRef
14. Suppression of PTEN/AKT signaling decreases the expression of TUBB3 and TOP2A with subsequent inhibition of cell growth and induction of apoptosis in human breast cancer MCF-7 cells via ATP and caspase-3 signaling pathways
    Zhenhua Yang et al, 2017, Oncology Reports CrossRef
15. Identification of Key Transcription Factors Associated with Lung Squamous Cell Carcinoma
    Feng Zhang et al, 2017, Medical Science Monitor CrossRef
16. Demethoxycurcumin sensitizes the response of non-small cell lung cancer to cisplatin through downregulation of TP and ERCC1-related pathways
    Chen-Yuan Lin et al, 2019, Phytomedicine CrossRef
17. Clinical significance of breast cancer susceptibility gene 1 expression in resected non-small cell lung cancer: A meta-analysis
    Yang Gao et al, 2021, World Journal of Clinical Cases CrossRef
18. Randomized Prospective Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum Therapy in Advanced Non–Small-Cell Lung Cancer: ERCC1 Trial (ET)
    Siow Ming Lee et al, 2017, Journal of Clinical Oncology CrossRef
19. A newly established monoclonal antibody against ERCC1 detects major isoforms of ERCC1 in gastric cancer
    Takayuki Oishi et al, 2021, Global Health & Medicine CrossRef
20. Overview of Oncology Biomarkers
    Mitsukuni Suenaga et al, 2016, Pharmacokinetics in Drug Development CrossRef
21. COMBINED TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER WITH PERSONALIZED PRESCRIPTION OF ADJUVANT CHEMOTHERAPY
    null null et al, 2019, AVICENNA BULLETIN CrossRef